RYTM
NASDAQ
US
Rhythm Pharmaceuticals, Inc. - Common Stock
$86.29
▼ $-1.83
(-2.08%)
Vol 546K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$7.1B
ROE
-101.6%
Margin
-110.3%
D/E
36.85
Beta
2.01
52W
$46–$122
Wall Street Consensus
22 analysts · Apr 20268
Strong Buy
12
Buy
2
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
KYMR
Kymera Therapeutics Inc
$6.1B
ACLX
Arcellx Inc
$3.8B
PTGX
Protagonist Therapeutics Inc
P/E 118.9
$5.5B
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
PTCT
PTC Therapeutics Inc
P/E 8.1
$6.1B
ERAS
Erasca Inc
$1.1B
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.84 | $-0.73 | +$0.11 |
| Sep 2025 | $-0.74 | $-0.82 | $-0.08 |
| Jun 2025 | $-0.69 | $-0.75 | $-0.06 |
| Mar 2025 | $-0.72 | $-0.81 | $-0.09 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -119.3% | -119.3% | -119.3% | -119.3% | -101.6% | -101.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -96.1% | -117.1% | -117.1% | -117.1% | -110.3% | -110.3% |
| Gross Margin | 88.6% | 89.2% | 89.2% | 89.2% | 89.4% | 89.4% |
| D/E Ratio | 82.19 | 82.19 | 82.19 | 82.19 | 36.85 | 36.85 |
| Current Ratio | 2.79 | 2.79 | 2.79 | 2.79 | 4.75 | 4.75 |
Key Ratios
ROA (TTM)
-46.4%
P/S (TTM)
40.98
P/B
20.9
EPS (TTM)
$-3.02
CF/Share
$-3.23
Rev Growth 3Y
+245.7%
52W High
$122.20
52W Low
$45.91
$45.91
52-Week Range
$122.20
How does RYTM compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RYTM valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
41.0
▲
219%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
20.9
▲
750%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RYTM profitability vs Biotechnology peers
ROE
-101.6%
▼
51%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-110.3%
▲
62%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
89.4%
▲
14%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-46.4%
▲
1%
above
peers
(-46.7%)
vs Peers
vs Industry
In line
RYTM financial health vs Biotechnology peers
D/E ratio
36.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.8
▲
7%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
2.0
▲
107%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
RYTM fundamentals radar
RYTM
Peer median
Industry
RYTM profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio